CDSCO approves AstraZeneca’s Dapagliflozin with additional indication for treating CKD and heart… EP News Bureau Nov 30, 2022 Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalisation for heart failure in adults with…
